2026-01-19 - Analysis Report
### Merck Financial Report
#### Company Overview
Merck - 면역 항암제 등 글로벌 혁신 제약사 (Innovative global pharmaceutical company)

#### Return Rate Comparison
* Cumulative return of review stock (MRK): -2.76%
* Cumulative return of comparison stock (VOO): 82.54%
* Divergence:
  - Max: N/A
  - Min: N/A
  - Current: N/A
  - Relative divergence: N/A

#### Alpha, Beta Analysis
| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 14.0% | 5.8% | 14.0% | 0.7 | 182.1B |
| 2017-2019  | 21.0% | 7.6% | 12.0% | 0.7 | 216.8B |
| 2018-2020  | 7.0% | 17.7% | -14.0% | 0.7 | 195.0B |
| 2019-2021  | -4.0% | 17.7% | -41.0% | 0.6 | 191.4B |
| 2020-2022  | 19.0% | 16.1% | 9.0% | 0.5 | 277.1B |
| 2021-2023  | 31.0% | 10.7% | 14.0% | 0.3 | 272.3B |
| 2022-2024  | 4.0% | 23.8% | -22.0% | 0.3 | 248.5B |
| 2023-2025  | -43.0% | 35.8% | -92.0% | 0.3 | 262.9B |

#### Recent Stock Price Fluctuations
* Close: $108.83
* Last-market: {'price': 108.83, 'previousClose': 110.97, 'change': -1.93}
* 5-day SMA: $109.65
* 20-day SMA: $107.19
* 60-day SMA: $98.44

#### RSI, PPO Index Indicators
* Market Risk Indicator (MRI): 0.80
* RSI: 56.63
* PPO: -0.18
* Hybrid Signal: Buy (Cash 40%)
* Risk Level: Medium (MRI 0.80)
* Recent (20 days) relative divergence change: 0.0
* 7-day Rank change: 0
* 7-day Dynamic Expected Return change: 0.0

#### Expected Return
* N/A

#### Recent News & Significant Events
[2026-01-18] Rep. Julie Johnson Sells Merck & Co., Inc. (NYSE:MRK) Stock - MarketBeat
[2026-01-15] Is Merck Stock A Trap At $110? - Forbes
[2026-01-15] What’s In Store For Merck Stock? - Trefis
[2026-01-14] Is Merck KGaA (XTRA:MRK) Share Price Misaligned With Cash Flow And Earnings Valuation Estimates - Yahoo Finance
[2026-01-16] Is Merck (MRK) Pricing In Its Recent Share Run Or Leaving Further Upside? - simplywall.st
[2026-01-18] Merck & Co., Inc. $MRK Stock Holdings Lowered by Pinnacle Financial Partners Inc - MarketBeat

#### Analyst Opinions
* Analyst Consensus:
  - Key: Buy
  - Mean (1=StrongBuy~5=Sell): 1.90 (~Buy)
  - Opinions: 27
  - Target Price (avg/high/low): 113.48 / 135.00 / 83.00

#### Recent Earnings Analysis
| Date | EPS | Revenue |
|---|---:|---:|
| 2025-11-05 | 2.32 | 17.28 B$ |
| 2025-08-05 | 1.76 | 15.81 B$ |
| 2025-05-02 | 2.01 | 15.53 B$ |
| 2024-11-06 | 1.25 | 16.66 B$ |
| 2025-11-05 | 1.25 | 16.66 B$ |

#### Financial Information
### Revenue and Profitability
| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $17.28B | 77.69% |
| 2025-06-30 | $15.81B | 77.50% |
| 2025-03-31 | $15.53B | 77.98% |
| 2024-12-31 | $15.62B | 75.50% |
| 2024-09-30 | $16.66B | 75.51% |

### Capital and Profitability
| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $51.85B | 11.16% |
| 2025-06-30 | $48.99B | 9.04% |
| 2025-03-31 | $48.34B | 10.51% |
| 2024-12-31 | $46.31B | 8.08% |
| 2024-09-30 | $44.50B | 7.09% |

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.